Dual‑directional effect of vinorelbine combined with cisplatin or fluorouracil on tumor growth and metastasis in metronomic chemotherapy in breast cancer

Liu,Hua; Li,Min; Lin,Yanlan; You,Huining; Kou,Jianrong; Feng,Weiyi

doi:10.3892/ijo.2023.5601

Dual‑directional effect of vinorelbine combined with cisplatin or fluorouracil on tumor growth and metastasis in metronomic chemotherapy in breast cancer

Authors:
- Hua Liu
- Min Li
- Yanlan Lin
- Huining You
- Jianrong Kou
- Weiyi Feng
View Affiliations

Affiliations: Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: December 8, 2023 https://doi.org/10.3892/ijo.2023.5601
Article Number: 13
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metronomic chemotherapy (MCT) regimens may be associated with risks to the patient due to the ambiguity surrounding low dosages and schedules. In the present study, metronomic regimens of vinorelbine (NVB) combined with cisplatin (CDDP) or fluorouracil (5‑FU) were chosen to study the dose‑response associations with tumor growth and metastasis, along with the underlying mechanisms in angiogenesis, apoptosis and tumor immunity, using experimental techniques such as immunofluorescence, immunohistochemistry, western blotting and flow cytometry. The results demonstrated a dual‑directional pharmacological action of promoting and suppressing tumor growth or metastasis in BALB/c mice bearing a 4T1 tumor at certain low and high doses of the drugs. Low doses of NVB combined with CDDP or 5‑FU accelerated tumor growth by enhancing angiogenesis, increasing the expression of angiogenic proteins, NF‑κB and osteopontin in tumor tissues, and inducing the accumulation of myeloid‑derived suppressor cells and macrophages. By contrast, higher doses inhibited tumor growth by suppressing these effects. Notably, the upregulation of apoptotic proteins was observed after low‑ and high‑dose treatments. Furthermore, at low concentrations, NVB combined with CDDP or 5‑FU stimulated certain functions of endothelial and tumor cells, including migration and invasion, whereas at higher concentrations they suppressed proliferation and induced apoptosis. Therefore, the results of the present study suggested the potential risks of metronomic combination chemotherapy by demonstrating that, at certain low doses, tumor growth or metastasis was promoted, and emphasized the existence of an effective dose interval that changes with different drug combinations. However, further studies are needed before a specific metronomic combination regimen can be administered clinically for cancer treatment.

View Figures

View References

1	Wong HH and Halford S: Dose-limiting toxicity and maximum tolerated dose: Still fit for purpose? Lancet Oncol. 16:1287–1288. 2015.
2	Gasparini G: Metronomic scheduling: The future of chemotherapy? Lancet Oncol. 2:733–740. 2001.
3	Pomeroy AE, Schmidt EV, Sorger PK and Palmer AC: Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer. 8:915–929. 2022.
4	Wu J and Waxman DJ: Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett. 419:210–221. 2018.
5	Chen YL, Chang MC and Cheng WF: Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett. 400:282–292. 2017.
6	Scharovsky OG, Rico MJ, Mainetti LE, Perroud HA and Rozados VR: Achievements and challenges in the use of metronomics for the treatment of breast cancer. Biochem Pharmacol. 175:1139092020.
7	Cox MC and Bocci G: Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds. Cancer Lett. 524:144–150. 2022.
8	Bocci G and Kerbel RS: Pharmacokinetics of metronomic chemotherapy: A neglected but crucial aspect. Nat Rev Clin Oncol. 13:659–673. 2016.
9	Lien K, Georgsdottir S, Sivanathan L, Chan K and Emmenegger U: Low-dose metronomic chemotherapy: A systematic literature analysis. Eur J Cancer. 49:3387–3395. 2013.
10	de Ruiter J, Cramer SJ, Smink T and van Putten LM: The facilitation of tumour growth in the lung by cyclophosphamide in artificial and spontaneous metastases models. Eur J Cancer. 15:1139–1149. 1979.
11	Chen Y, Liu H, Zheng Q, Li H, You H, Feng Y and Feng W: Promotion of tumor progression induced by continuous low-dose administration of antineoplastic agent gemcitabine or gemcitabine combined with cisplatin. Life Sci. 306:1208262022.
12	Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, et al: Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 26:4899–4905. 2008.
13	Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, et al: Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. Cancer Lett. 400:276–281. 2017.
14	Rossi D: Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience. Lung Cancer. 145:83–84. 2020.
15	Xu B, Sun T, Wang S and Lin Y: Metronomic therapy in advanced breast cancer and NSCLC: Vinorelbine as a paradigm of recent progress. Expert Rev Anticancer Ther. 21:71–79. 2021.
16	Riesco-Martinez M, Parra K, Saluja R, Francia G and Emmenegger U: Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett. 400:311–318. 2017.
17	Munzone E and Colleoni M: Clinical overview of metronomic chemotherapy in breast cancer. Nat Rev Clin Oncol. 12:631–644. 2015.
18	Romani AMP: Cisplatin in cancer treatment. Biochem Pharmacol. 206:1153232022.
19	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003.
20	National Research Council Committee for the Update of the Guide for the Care and Use of Laboratory Animals: The National Academies Collection: Reports funded by National Institutes of Health. Guide for the Care and Use of Laboratory Animals. National Academy of Sciences, National Academies Press; Washington, DC: 2011
21	Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA and Lesterhuis WJ: A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 17:6842017.
22	Saif MW and von Borstel R: 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): Toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol. 58:136–142. 2006.
23	Navari RM and Aapro M: Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 374:1356–1367. 2016.
24	Xu Y, Ye S, Zhang N, Zheng S, Liu H, Zhou K, Wang L, Cao Y, Sun P and Wang T: The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun (Lond). 40:484–500. 2020.
25	Magaki S, Hojat SA, Wei B, So A and Yong WH: An introduction to the performance of immunohistochemistry. Methods Mol Biol. 1897:289–298. 2019.
26	Zhang S, Liu Y, Xiang D, Yang J, Liu D, Ren X and Zhang C: Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury. Biomed Pharmacother. 106:910–916. 2018.
27	Deng J, Yang H, Haak VM, Yang J, Kipper FC, Barksdale C, Hwang SH, Gartung A, Bielenberg DR, Subbian S, et al: Eicosanoid regulation of debris-stimulated metastasis. Proc Natl Acad Sci USA. 118:e21077711182021.
28	Chang J, Bhasin SS, Bielenberg DR, Sukhatme VP, Bhasin M, Huang S, Kieran MW and Panigrahy D: Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. FASEB J. 33:114–125. 2019.
29	Yin Y, Zeng K, Wu M, Ding Y, Zhao M and Chen Q: The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer. Cell Biochemistry Biophysics. 70:1145–1151. 2014.
30	Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, Abdool A, Thomas D, Yeh C, O'Brien S and Albitar M: Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res. 34:173–176. 2010.
31	Safarzadeh E, Orangi M, Mohammadi H, Babaie F and Baradaran B: Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis. J Cell Physiol. 233:3024–3036. 2018.
32	Cassetta L and Pollard JW: Targeting macrophages: Therapeutic approaches in cancer. Nature reviews Drug Discovery. 17:887–904. 2018.
33	Chen Y, Zhang S, Wang Q and Zhang X: Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 10:362017.
34	Barbolosi D, Ciccolini J, Lacarelle B, Barlési F and André N: Computational oncology-mathematical modelling of drug regimens for precision medicine. Nat Rev Clin Oncol. 13:242–254. 2016.
35	Ebos JM and Kerbel RS: Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 8:210–221. 2011.
36	Zhang T, Zhang L, Gao Y, Wang Y, Liu Y, Zhang H, Wang Q, Hu F, Li J, Tan J, et al: Role of aneuploid circulating tumor cells and CD31⁺ circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced NSCLC. Mol Oncol. 15:2891–2909. 2021.
37	Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M, Frasca D, Koker M, König K, Meder L, et al: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 123:1732–1740. 2013.
38	Freire Valls A, Knipper K, Giannakouri E, Sarachaga V, Hinterkopf S, Wuehrl M, Shen Y, Radhakrishnan P, Klose J, Ulrich A, et al: VEGFR1⁺ Metastasis-associated macrophages contribute to metastatic angiogenesis and influence colorectal cancer patient outcome. Clin Cancer Res. 25:5674–5685. 2019.
39	Liu W, Xu J, Wang M, Wang Q, Bi Y and Han M: Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol. 39:1213–1220. 2011.
40	Riedel F, Götte K, Schwalb J, Bergler W and Hörmann K: Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol. 17:1099–1105. 2000.
41	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010.
42	Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006.
43	Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878–1886. 2000.
44	Silva F, Padin-Iruegas ME, Caponio VCA, Lorenzo-Pouso AI, Saavedra-Nieves P, Chamorro-Petronacci CM, Suarez-Penaranda J and Perez-Sayans M: Caspase 3 and cleaved Caspase 3 expression in tumorogenesis and its correlations with prognosis in head and neck cancer: A systematic review and meta-analysis. Int J Mol Sci. 23:119372022.
45	Tummers B and Green DR: Caspase-8: regulating life and death. Immunol Rev. 277:76–89. 2017.
46	Haak VM, Huang S and Panigrahy D: Debris-stimulated tumor growth: A Pandora's box? Cancer Metastasis Rev. 40:791–801. 2021.
47	Huang JS, Yang CM, Wang JS, Liou HH, Hsieh IC, Li GC, Huang SJ, Shu CW, Fu TY, Lin YC, et al: Caspase-3 expression in tumorigenesis and prognosis of buccal mucosa squamous cell carcinoma. Oncotarget. 8:84237–84247. 2017.
48	Weigert A, Mora J, Sekar D, Syed S and Brüne B: Killing is not enough: How apoptosis hijacks tumor-associated macrophages to promote cancer progression. Adv Exp Med Biol. 930:205–239. 2016.
49	Revesz L: Effect of tumour cells killed by x-rays upon the growth of admixed viable cells. Nature. 178:1391–1392. 1956.
50	Donato AL, Huang Q, Liu X, Li F, Zimmerman MA and Li CY: Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. J Invest Dermatol. 134:1686–1692. 2014.
51	Fritsch M, Günther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, Schiffmann LM, Stair N, Stocks H, Seeger JM, et al: Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 575:683–687. 2019.
52	Fianco G, Contadini C, Ferri A, Cirotti C, Stagni V and Barilà D: Caspase-8: A novel target to overcome resistance to chemotherapy in glioblastoma. Int J Mol Sci. 19:37982018.
53	Zhu CC, Chen C, Xu ZQ, Zhao JK, Ou BC, Sun J, Zheng MH, Zong YP and Lu AG: CCR6 promotes tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer. Biochim Biophys Acta Mol Basis Dis. 1864:387–397. 2018.
54	Lang S, Bruderek K, Kaspar C, Höing B, Kanaan O, Dominas N, Hussain T, Droege F, Eyth C, Hadaschik B and Brandau S: Clinical relevance and suppressive capacity of human Myeloid-derived suppressor cell subsets. Clin Cancer Res. 24:4834–4844. 2018.
55	Udumula MP, Sakr S, Dar S, Alvero AB, Ali-Fehmi R, Abdulfatah E, Li J, Jiang J, Tang A, Buekers T, et al: Ovarian cancer modulates the immunosuppressive function of CD11b⁺Gr1⁺ myeloid cells via glutamine metabolism. Mol Metab. 53:1012722021.
56	Nielsen SR and Schmid MC: Macrophages as Key drivers of cancer progression and metastasis. Mediators Inflamm. 2017:96247602017.
57	Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA and Ostrand-Rosenberg S: Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol. 96:1109–1118. 2014.